Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Protalix
ClinicalTrials.gov Identifier:
NCT01678898
First received: August 31, 2012
Last updated: April 18, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2016
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)